Most analysts are forcasting approval in Q1/Q2 2010 now.
That seems like a plausible explanation for the relatively low share price. A synthetic generic should be relatively low-risk for FDA approval (I'm assuming 10% chance of completely rejection, and even that seems excessive) but a three month delay would certainly flush out some more sellers.
Most analysts are forcasting approval in Q1/Q2 2010 now.That...
Add TSN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable